Sensitive Simultaneous Measurement of Metformin and Linagliptin in Plasma Samples by Couple of Nano Graphene Oxide-based Dispersive Solid Phase Extraction Method and Liquid Chromatography

Document Type : Research article


1 Department of Analytical Chemistry, Faculty of Science, University of Kashan, Kashan, Iran.

2 Department of Food Science and Technology, Faculty of Food Industry and Agriculture, Standard Research Institute (SRI), Karaj, Iran.


A simple, rapid, and ultra sensitive dispersive solid phase extraction based on nano graphene oxide was developed for simultaneous measurement of trace amounts of metformin (MET) and linagliptin (LIN) in plasma samples by HPLC-UV-Vis. Affecting factors on the extraction of these drugs, including adsorbent weight, extraction time, organic solvent type, desorption situations, and composition of solvent were examined and optimized. In optimum conditions, the LOD (limit of detection) and LOQ (limit of quantification) of the suggested technique were 2.0 ngmL-1 and 6.1 (ngmL-1) for LIN and 3.0 ngmL-1 and 9.2 ngmL-1 for MET, respectively. Suitable linear behavior in the considered ranges of concentration (10-2000 ngmL-1) and good correlation coefficient of 0.9901 and 0.9903 (r2) for LIN and MET were obtained, respectively. The RSD (relative standard deviations) according to three replicate measurements at 2, 20, 200 ngmL-1 levels of these drugs was less than 8.0%. In the last step, applicability of the suggested technique was examined by analyzing the drugs in plasma samples and reasonable results were achieved.

Graphical Abstract

Sensitive Simultaneous Measurement of Metformin and Linagliptin in Plasma Samples by Couple of Nano Graphene Oxide-based Dispersive Solid Phase Extraction Method and Liquid Chromatography


[1] T. Haak, Combination of linagliptin and metformin for the treatment of patients with type 2 diabetes, Clinical medicine insights. J. Diabetes Endocrinology 8 (2015) 1.
[2]S. Del Prato, A.H. Barnett, H. Huisman, D. Neubacher, H.J. Woerle, K.A. Dugi, Effect of linagliptin monotherapy on glycaemic control and markers of β‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 3(2011)258-67.
[3]M.R. Taskinen, J. Rosenstock, I. Tamminen, R. Kubiak, S .Patel, K.A. Dugi, Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study. Diabetes Obes Metab. 13 (1)(2011)65-74.
[4]S.A. Ross, E. Rafeiro, T. Meinicke, R .Toorawa, S. Weber-Born, H.J.  Woerle ,Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Curr Med Res Opin. 28 (9)(2012)1465-74.
[5]S. Correia, C. Carvalho, M.S. Santos, R. Seiça, C.R. Oliveira, P.I. Moreira, Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. Mini reviews in medicinal chemistry 13 (2008)1343-54.
[6]Y. Terawaki, T. Nomiyama, H .Takahashi, Y. Tsutsumi, K. Murase, R. Nagaishi, Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis. Diabetol Metab Syndr. 7(2015)44.
[7]N. Padmaja and G. Veerabhadram, Development and Validation of Analytical Method for Simultaneous Estimation of Empaglifozin and Linagliptin in Bulk Drugs and Combined Dosage Forms Using UV-Visible Spectroscopy. Der Pharmacia Lettre.7(2015) 306–312.
[8]L. R. Badugu, A Validated RP-HPLC method for the determination of Linagliptin, Am. J. Pharmtech Res. 2(2012) 463–470.
[9]S. P.Banik, P. Karmakar , M. A. H. Miah, Development and Validation of a UV-Spectrophotometric Method for Determination of Vildagliptin and Linagliptin in Bulk and Pharmaceutical Dosage Forms.Bangladesh Pharm. J. 18(2015)163–168.
[10]R. Gomis, R.M. Espadero, R .Jones, H.J. Woerle, K.A. Dugi, Efficacy and safety of initial combination  therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double‐blind, placebo‐controlled study. Diabetes Obes Metab.13 (7)(2011)653-61.
[11]R.A. DeFronzo, A. Lewin, S .Patel, D. Liu, R. Kaste, H.J. Woerle, Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes care. 38 (3)(2015)384-93.
[12]N.M. Maruthur, E. Tseng, S. Hutfless, L.M. Wilson, C .Suarez-Cuervo, Z .Berger,Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 164 (11) (2016 )740-51.
[13]J.M. Evans, L.A. Donnelly, A.M. Emslie-Smith, D.R. Alessi, A.D. Morris. Metformin and reduced risk of cancer in diabetic patients. BMJ. 330 (7503) (2005)1304-5.
[14]E.Moll, F. van der Veen, M. van Wely,The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 6 (2007)527-37.
[15] K. Scida, P.W. Stege, G. Haby, G.A. Messina, C.D. García, Recent applications of carbon-based nanomaterials in analytical chemistry: critical review, Anal.Chim. Acta 691 (2011) 6–7.
[16] M. Valcárcel, S. Cárdenas, B.M. Simonet, Y. Moliner-Martínez, R. Lucena,Carbon nanostructures as sorbent materials in analytical processes, TrAC,Trends Anal. Chem. 27 (2008) 34–43.
[17] G.Z. Kyzas, A.Koltsakidou, S.G. Nanaki, D.N. Bikiaris, D.A. Lambropoulou ,Removal of beta-blockers from aqueous media by adsorption onto graphene oxide, Science of the Total Environment 537 (2015) 411 –420.
[18] B.H. Fumes, M.R. Silva, F.N. Andrade, C.E.D. Nazario, F.M. Lanc¸ Recent advances and future trends in new materials for sample preparation, TrAC,Trends Anal. Chem. 71 (2015) 9–25.
[19] Q. Liu, J. Shi, G. Jiang, Application of graphene in analytical sample preparation, TrAC, Trends Anal. Chem. 37 (2012) 1–11.
[20] G.Liu, W.Jiang, Y.Wang, S. Zhong, D. Sun, J. Liu, One-pot synthesis of Ag@Fe3O4/reduced graphene oxide composite with excellent electromagnetic absorption properties. Ceram. Int. 41(2015) 4982 –4988.
[21]S. Zhu, Y.Liu , S.Liu , G.Zeng , L.Jiang , X.Tan, L. Zhou, W.Zeng, T.Li, C.Yang, Adsorption of emerging contaminant metformin using graphene oxide, Chemosphere 179 (2017) 20-28.
[22]C. Laginhas, J.M. Valente Nabais, M.M. Titirici, Metformin adsorption onto activated carbons prepared by hydrothermal carbonization and activation. Livro de resumos da 40 Reunião Ibérica de Adsorção (2016) 121-122.
[23]G .Zhou, R .Myers, Y. Li, Y. Chen, X .Shen,J. Fenyk-Melody , Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin Invest. 108 (2001)1167-74.
[24]K.Y.Kavitha, G. Geetha, R. Hariprasad, M. Kaviarasu, R. Venkatnarayanan, Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of Linagliptin and Metformin in pure and pharmaceutical dosage form. J. Chem. Pharm. Res.5( 2013) 230–235.
[25]D. Thakare, V. Patil, K. Ramesh, V.B. Jadhav, C.K. Sekhar, A New RP-HPLC method for Simultaneous estimation of Metformin HCl and Linagliptin tablet dosage form. World J. Pharm. Pharmaceutical Sci. 2( 2013)1332-1341.
[26]R.I.El-Bagary, E.F. Elkady, B.M. Ayoub, Spectrophotometric Methods for the
Determination of Linagliptin in Binary Mixture with Metformin Hydrochloride and
Simultaneous Determination of Linagliptin and Metformin Hydrochloride using High Performance Liquid Chromatography. Int. J. Biomed. Sci. 9( 2013)41–47.
[27]M.Attimarad, S. H.Nagaraja, B.E. Aldhubaib, A.Nair , K. N. Venugopala, Simultaneous Determination of Metformin and Three Gliptins in Pharmaceutical Formulations Using RP HPLC: Application to Stability Studies on Linagliptin Tablet Formulation, Indian Journal of Pharmaceutical Education and Research 48 ( 4 ) (2014 ) 45-53.
[28] P. B. N. Prasad, K. Satyanaryana, G. Krishnamohan, Development and Validation of A Stability Indicating Method for Simultaneous Determination of Metformin Hydrochloride and Linagliptin in A Formulation by RP-HPLC. International Journal of Pharma Research and Review 5(6)(2016)16-22.
[29]J.A. Swamy, H.K. Baba,Analytical Method development and Method validation for the simultaneous estimation of Metformin HCL and Linagliptin in Bulk and tablet Dosage Form by RP-HPLC Method. Int. J. Pharm. 3( 2013)594-600.
[30]D .Singh‐Franco, J. McLaughlin‐Middlekauff, S. Elrod, C .Harrington,The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis. Diabetes Obes Metab. 14 (8)(2012)694-708.
[31]S.Donepudia, S.Achantab, Validated HPLC-UV method for simultaneous estimation of Linagliptin and Empagliptin in human plasma. International Journal of Applied Pharmaceutics 10(3)( 2018).